Aculys Pharma and Four H have announced a research collaboration to explore the potential of wearable devices to improve clinical trial outcomes. The partnership will combine Aculys’ proprietary data analytics platform with Four H’s wearable device technology to better understand and predict patient behaviors, such as adherence to medication regimens and symptom tracking. The collaboration will focus on leveraging the data collected from these devices to improve the accuracy of clinical trial outcomes and to develop more personalized treatments for patients. This groundbreaking collaboration has the potential to revolutionize how clinical trials are conducted and ultimately improve patient outcomes.
Aculys Pharma and Four H enter into an exploratory research collaboration to study sleep disorders in Japan
Aculys Pharma and Four H have announced a research collaboration using wearable devices. This will help patients with narcolepsy and EDS[1] associated with OSAS[2]. Aculys Pharma recently established a new pharmaceutical model, DX (digital transformation), in its clinical trials and medicines. According to this agreement, Four H is responsible for launching the collaborative exploratory study. At the same time, Aculys will be responsible for collecting the participants’ subjective assessment of their sleep. Besides this, Aculys will also collate the data of the patient’s sleep, activities, and heart rate acquired from the wearable devices. The patients will wear devices each night during the clinical trial period. In conjunction with the other data obtained by the clinical trials, these data will be analyzed to identify sleep-related digital biomarkers.
Aculys Pharma and Four H Research Collaboration
Through this collaboration, both companies aim to get an objective understanding of narcolepsy, OSAS, and its characteristics. OSAS, obstructive sleep apnea syndrome, is characterized by repetitive episodes of nocturnal breathing cessation due to upper airway collapse.
Moreover, they plan to analyze using AI[3] and other methods. The subjective and objective assessments of the patient’s data obtained by the wearable device. Additionally, through collation and analysis of these data, they plan to develop appropriate digital biomarkers for future clinical trials and clinical settings.
The critical outcomes anticipated in this study are an objective understanding of the patient’s sleep status, analysis of daytime sleepiness patterns, and extraction of sleep characteristics. Other information to be obtained from this study are daytime activity data through comparison with people without symptoms and detection of predictive signs of the onset of daytime sleepiness.
The pharma companies have asserted that this study will help provide an accurate understanding of each patient’s sleep and lifestyle patterns. They also plan to collectively build a comprehensive sleep ecosystem for patients in the long run. This ecosystem will include several components like digital biomarkers to predict health risks and personalized data to improve quality of life and productivity. Additionally, the companies have emphasized that this will entail a quality disease management program that patients can utilize at home.
Know the Abbreviations
1. EDS- Excessive Daytime Sleepiness
Excessive daytime sleepiness (EDS) is a condition that causes a person to feel excessively sleepy during the day, even after getting adequate sleep at night. Various factors, such as sleep deprivation, medical conditions, certain medications, or lifestyle factors, can cause it. Symptoms of EDS include difficulty waking up in the morning, feeling tired throughout the day, difficulty concentrating, and an increased need for naps. Treatments for EDS vary depending on the underlying cause and may include lifestyle changes, medications, and other therapies.
2. OSAS- Obstructive Sleep Apnea Syndrome
Obstructive sleep apnea (OSA) is a common disorder when a person’s breathing is repeatedly interrupted during sleep. An airway blockage causes it, usually when the soft tissue in the back of the throat collapses and closes during sleep. OSA is characterized by loud snoring, choking or gasping for air, and daytime sleepiness. People with OSA may also experience dry mouth, morning headaches, difficulty concentrating, and irritability. It is one of the most common sleep-related breathing disorders and can lead to significant health problems, including excessive daytime sleepiness, hypertension, and cardiac arrhythmias. OSA is usually treated with lifestyle changes and medical interventions, such as continuous positive airway pressure (CPAP) therapy, weight loss, and/or oral appliance therapy.
3. AI- Artificial Intelligence
Artificial Intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. Artificial Intelligence (AI) is increasingly used in healthcare to improve patient care and outcomes. AI-driven technologies are used in various ways, such as medical imaging, natural language processing, and clinical decision support. AI can help reduce medical errors, improve accuracy, and reduce costs. It can also facilitate better communication between patients and healthcare providers and help to provide more personalized care. AI can also identify potential health risks and diseases earlier, provide smarter drug development and personalized treatments, and provide more accurate diagnoses. AI holds great potential for transforming healthcare, and its use is growing rapidly.
Read more:
- Milestones in Cancer Research and Discovery
- Pharma News Weekly Update (Week 1-Dec’22)
- Pharma News August 2021
- Monthly Update- pharma News July 2021
- Moderna collaborates with Thermo Fischer Scientific.
- Bamlanivimab and Etesevimab: EUA in India
- JB Chemicals launches NOSMOK nicotine lozenges
- 2-DG: anti-COVID-19 by the INMAS
- GSK and Vir Biotechnology plan to launch Sotrovimab
- USFDA approves Gland Pharma’s Foscarnet